Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zimmer Biomet Holdings, Inc. (NYSE: ZBH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zimmer Biomet is a global medical technology company focused on musculoskeletal health and orthopedic implants, and its filings offer detailed insight into its operations, capital structure, risk factors and governance.
Through this page, you can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss Zimmer Biomet’s product categories such as knees, hips, sports medicine, extremities, trauma, craniomaxillofacial and thoracic (S.E.T.), and technology and data, bone cement and surgical. These reports typically include segment and geographic sales information, descriptions of the company’s digital and robotic technologies, and management’s discussion and analysis.
You will also find current reports on Form 8-K covering material events, including quarterly earnings releases, new debt issuances, revolving credit agreements, acquisitions such as the merger with Monogram Technologies Inc., and other significant corporate developments. Filings describing the company’s notes and bonds, including series listed on the New York Stock Exchange, provide detail on interest rates, maturities, covenants and redemption features.
Stock Titan enhances these documents with AI-powered summaries that explain key points in clear language, helping users navigate complex topics like non-GAAP financial measures, leverage covenants and transaction structures. The platform also surfaces insider and executive-related filings, such as those reporting departures or appointments of certain officers, so users can track governance changes. With real-time updates from EDGAR and AI-generated highlights, this page is a focused resource for analyzing Zimmer Biomet’s SEC reporting history and ongoing regulatory disclosures.
Zimmer Biomet Holdings, Inc. is asking shareholders to vote at its May 22, 2026 virtual annual meeting on four key items: electing 10 directors, ratifying PricewaterhouseCoopers as auditor for 2026, approving executive pay on an advisory basis, and a shareholder proposal for an independent board chairman.
The Board highlights a largely independent, skills-diverse slate, strong governance features such as majority voting, proxy access, board evaluations and stock ownership guidelines, and an enhanced Lead Independent Director role when the CEO also serves as Chairman. The company reports 2025 net sales growth of 7.2%, aided by acquisitions and new products, and explains that over 90% of the CEO’s 2025 target pay was performance-based, with annual bonuses and performance stock units tied to constant currency revenue growth, adjusted earnings, free cash flow and relative total shareholder return.
Zimmer Biomet Holdings Inc ownership update: The Vanguard Group filed Amendment No. 9 to a Schedule 13G/A disclosing that it beneficially owns 0 shares of Common Stock, representing 0%. The filing explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report holdings separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported an open-market sale of company stock. She sold 2,650 shares of common stock at an average price of $94.66 per share. After this transaction, she directly holds 10,224 shares of Zimmer Biomet common stock.
ZBH submitted a Form 144 listing proposed transactions in Common Stock tied to restricted stock vesting events. The filing lists vesting entries dated 03/06/2025, 02/20/2026, 02/25/2026, and 03/06/2026 with quantities including 1, 1,162, 1,423, and 64 shares respectively. The excerpt names Fidelity Brokerage Services LLC as a broker/agent and references the NYSE.
Zimmer Biomet Holdings Exec VP & CFO Suketu Upadhyay exercised restricted stock units into 14,776 shares of common stock on March 6, 2026. To cover tax obligations on this RSU vesting, 6,576 shares were withheld by the company at $92.54 per share. After these compensation-related transactions, Upadhyay directly holds 69,485 shares of Zimmer Biomet common stock.
Zimmer Biomet Holdings, Inc. Group President EMEA Wilfred Van Zuilen exercised restricted stock units on March 6, 2026, converting 7,004 RSUs into common shares. The company withheld 1,822 shares at $92.54 per share to cover tax obligations, leaving a net 5,182 shares. Following these compensation-related transactions, he directly holds 30,991 shares of common stock.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported routine equity compensation activity. On March 6, 2026, restricted stock units converted into 5,634 shares of common stock, with each RSU representing one share.
To cover tax withholding obligations on the RSU vesting, the company withheld 2,178 shares at a reference price of $92.54 per share, as disclosed. After these transactions, Winkler directly owns 12,874 shares of Zimmer Biomet common stock. The filing shows no open‑market purchases or sales, only RSU vesting and tax withholding.
Zimmer Biomet Holdings executive Yi Sang, Group President, Asia Pacific, reported the exercise and conversion of restricted stock units into common stock. On March 6, 2026, he exercised a total of 9,414 restricted stock units, receiving an equal number of common shares.
Following these transactions, Yi Sang directly owned 32,251 shares of common stock. The restricted stock units converted at no cash exercise price, reflecting the vesting of equity-based compensation rather than open-market purchases or sales.
ZIMMER BIOMET HOLDINGS, INC. executive Paul A. Stellato, VP, Controller and Chief Accounting Officer, reported routine equity compensation activity. On March 6, 2026, restricted stock units covering 1,363 shares and 607 shares were converted into the same number of shares of common stock.
To cover related tax withholding on these vestings, the company retained 633 shares and 282 shares of common stock at $92.54 per share, as described in the footnotes. After these transactions, Stellato directly held 5,582 shares of Zimmer Biomet common stock.
ZIMMER BIOMET HOLDINGS, INC. executive Chad F. Phipps exercised restricted stock units into common stock and used a portion of the resulting shares to cover taxes. On March 6, 2026, RSUs representing 6,786 shares of common stock were converted.
The company withheld a total of 2,732 shares of common stock at $92.54 per share to satisfy tax withholding obligations, as disclosed in the footnotes. After these transactions, Phipps directly owned 67,760 shares of Zimmer Biomet common stock. These events reflect compensation-related vesting and tax withholding rather than open-market trading.